Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.

Trial Details

NCT ID
NCT05800340
Phase
PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Toripalimab
  • Nab paclitaxel
  • Pemetrexed
  • Carboplatin
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Age: 18 Years and older
  • ECOG physical score 0-1 points; expected survival time ≥ 3 months;
  • Pathologically confirmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E …
  • Lung function capacity capable of tolerating the proposed lung surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →